Combination therapies for kidney cancer

The following is a Practice Update interview with Dr Hans Hammers, Associate Professor, Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas. During this interview, Dr Hammers talks about the upcoming combination therapies for the treatment of metastatic renal cell carcinoma (mRCC), such as nivolumab/ipilimumab, axitinib/pembrolizumab, cabozantinib/nivolumab, tivozanib/nivolumab and bevacizumab/atezolizumab combinations currently in development. The clinical trials […]

read more

New insights into immune-related adverse events in genitourinary cancers

The following is an interview with Dr Tanya Dorff, Associate Clinical Professor; Head, GU Cancer Program, City of Hope Hospital, California, where she discusses the results from a study looking at immune-related adverse events (irAEs) with immunotherapy drugs for the treatment of genitourinary cancers. The study that Dr Dorff talks about was presented at the American Society of Clinical Oncology Genitourinary […]

read more

KCSN Trustee appointed as Cancer Research UK Senior Clinical Advisor in clinical research

Cancer Research UK announces the appointment of Dr James Larkin as a new Senior Clinical Advisor in clinical research. Dr Larkin’s new role aims to accelerate the progress of the charity’s clinical research portfolio. He will also support the charity in helping ensure the UK can continue to participate in clinical trials across Europe after […]

read more

Potential role for high dose IL2 in metastatic kidney cancer

The following is an interview with Dr Tanya Dorff, Associate Clinical Professor; Head, GU Cancer Program, City of Hope Hospital, California, where she discusses a potential role for high dose interleukin 2 (IL2) for the treatment of metastatic renal cell carcinoma (mRCC). The study that Dr Dorff talks about was presented at the American Society of Clinical […]

read more

First-line immunotherapy for metastatic kidney cancer

The following is a Practice Update interview with Dr Eric Jonasch, Professor of genitourinary medical oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas. During this interview, Dr Jonasch talks about the upcoming immunotherapy combinations for use in the first-line for the treatment of metastatic renal cell carcinoma (mRCC), as well as […]

read more

Managing adverse events for cancer immunotherapies

Immunotherapy treatments for cancer hold great promise, but also come with their fair share of problems; an increasing number of unique and unexpected adverse events, sometimes appearing long after treatment with immunotherapy ends. The Society for Immunotherapy of Cancer has formed a Toxicity Management Working Group and published a position paper in the Journal of Cancer Immunotherapy in […]

read more

Cancer-killing virus acts by triggering the immune system

A study published in Cancer Research last week has shown that a cancer-killing (oncolytic) virus currently in clinical trials may also function as a cancer vaccine. In addition to killing some cancer cells directly, the virus alerts the immune system to the presence of a tumour, triggering a powerful, widespread immune response that kills cancer […]

read more

Status of adjuvant therapy for the treatment of kidney cancer

Dr Naomi Haas from Abramson Cancer Centre, Philadelphia, presented an overview of adjuvant therapy with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) in patients with high-risk renal cell carcinoma (RCC) at the American Society for Clinical Oncology Genitourinary (ASCO GU) 2018 meeting in San Francisco this month. Over the past few years, three […]

read more

Tyrosine kinase inhibitors for kidney cancer: Past, present and future

In his keynote lecture at the American Society for Clinical Oncology Genitourinary (ASCO GU) 2018 meeting in San Francisco this month, Dr Robert Motzer from Memorial Sloan Kettering Cancer Center in New York discussed the past, present and future of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) for the treatment of advanced/metastatic renal cell carcinoma […]

read more

The future of immuno-oncology in kidney cancer

In his keynote lecture at the American Society for Clinical Oncology Genitourinary (ASCO GU) 2018 meeting in San Francisco this month, Dr Bernard Escudier from the Institut Gustave Roussy in Villejuif, France, discussed the future of immuno-oncology in renal cell carcinoma (RCC). The current landscape of immune-oncology has been shaped by the results from the […]

read more
Showing 1 to 10 of 255 results
  TOP